410 related articles for article (PubMed ID: 33001202)
1. Association of Pretreatment With P2Y12 Receptor Antagonists Preceding Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndromes With Outcomes.
Dworeck C; Redfors B; Angerås O; Haraldsson I; Odenstedt J; Ioanes D; Petursson P; Völz S; Persson J; Koul S; Venetsanos D; Ulvenstam A; Hofmann R; Jensen J; Albertsson P; Råmunddal T; Jeppsson A; Erlinge D; Omerovic E
JAMA Netw Open; 2020 Oct; 3(10):e2018735. PubMed ID: 33001202
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with P2Y12 receptor antagonists in ST-elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry.
Redfors B; Dworeck C; Haraldsson I; Angerås O; Odenstedt J; Ioanes D; Petursson P; Völz S; Albertsson P; Råmunddal T; Persson J; Koul S; Erlinge D; Omerovic E
Eur Heart J; 2019 Apr; 40(15):1202-1210. PubMed ID: 30851037
[TBL] [Abstract][Full Text] [Related]
3. Precatheterization Use of P2Y
Badri M; Abdelbaky A; Li S; Chiswell K; Wang TY
J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28939715
[TBL] [Abstract][Full Text] [Related]
4. Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients.
Lattuca B; Belardi D; Demattei C; Schmutz L; Cornillet L; Ledermann B; Macia JC; Iemmi A; Gervasoni R; Roubille F; Cung TT; Robert P; Messner-Pellenc P; Leclercq F; Cayla G
J Invasive Cardiol; 2018 Sep; 30(9):348-354. PubMed ID: 30012889
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis.
Dawson LP; Chen D; Dagan M; Bloom J; Taylor A; Duffy SJ; Shaw J; Lefkovits J; Stub D
JAMA Netw Open; 2021 Nov; 4(11):e2134322. PubMed ID: 34797371
[TBL] [Abstract][Full Text] [Related]
6. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
[TBL] [Abstract][Full Text] [Related]
7. Impact of Society Guidelines on Trends in Use of Newer P2Y
Mohamed MO; Kontopantelis E; Alasnag M; Abid L; Banerjee A; Sharp ASP; Bourantas C; Sirker A; Curzen N; Mamas MA
J Am Heart Assoc; 2024 May; 13(9):e034414. PubMed ID: 38700032
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor is Not Superior to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI: A Report from Swedish Coronary Angiography and Angioplasty Registry.
Völz S; Petursson P; Odenstedt J; Ioanes D; Haraldsson I; Angerås O; Dworeck C; Hirlekar G; Myredal A; Albertsson P; Råmunddal T; Redfors B; Omerovic E
J Am Heart Assoc; 2020 Jul; 9(14):e015990. PubMed ID: 32662350
[TBL] [Abstract][Full Text] [Related]
9. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
[TBL] [Abstract][Full Text] [Related]
10. [Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
De Luca L; Pennacchi M; Musumeci G; D'Ascenzo F; Gallo P; Rigattieri S; Granatelli A; Berti S; Gulizia MM; De Servi S; Bolognese L;
G Ital Cardiol (Rome); 2018 Feb; 19(2):101-110. PubMed ID: 29531382
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania.
Cotoban AG; Udroiu CA; Vinereanu D
Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478
[TBL] [Abstract][Full Text] [Related]
12. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
[TBL] [Abstract][Full Text] [Related]
13. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
[TBL] [Abstract][Full Text] [Related]
14. Timing of P2Y
Almendro-Delia M; Hernández-Meneses B; Padilla-Rodríguez G; Blanco-Ponce E; Arboleda-Sánchez JA; Rodríguez-Yáñez JC; Soto-Blanco JM; Fernández-García I; Castillo-Caballero JM; García-Rubira JC; Hidalgo-Urbano R
J Am Coll Cardiol; 2024 Jun; 83(25):2629-2639. PubMed ID: 38897672
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment With P2Y12 Inhibitors in Patients With Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the Swedish Coronary Angiography and Angioplasty Registry.
Jurga J; Szummer KE; Lewinter C; Mellbin L; Götberg M; Zwackman S; Nilsson J; Völz S; Erlinge D; Persson J; Omerovic E; Jernberg T; Venetsanos D
Circ Cardiovasc Interv; 2021 Nov; 14(11):e010849. PubMed ID: 34592825
[TBL] [Abstract][Full Text] [Related]
17. No Benefit of Ticagrelor Pretreatment Compared With Treatment During Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Koul S; Smith JG; Götberg M; Omerovic E; Alfredsson J; Venetsanos D; Persson J; Jensen J; Lagerqvist B; Redfors B; James S; Erlinge D
Circ Cardiovasc Interv; 2018 Mar; 11(3):e005528. PubMed ID: 29870381
[TBL] [Abstract][Full Text] [Related]
18. Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Liu HL; Wei YJ; Jin ZG; Zhang J; Ding P; Yang SL; Luo JP; Ma DX; Liu Y; Han W
Medicine (Baltimore); 2016 May; 95(22):e3756. PubMed ID: 27258504
[TBL] [Abstract][Full Text] [Related]
19. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
[TBL] [Abstract][Full Text] [Related]
20. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
